Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 5:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 98 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Functional Constipation Clear all
Terminated Not applicable Interventional Accepts healthy volunteers

A Trial of Three Types of Enemas Used to Treat Functional Constipation in Children

NCT01823848
View directory record Official record
Conditions
Functional Constipation
Interventions
Sodium phosphate enema, Normal saline enema, Mineral oil enema
Drug
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
4 Years to 12 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 31, 2023 · Synced Jul 22, 2026, 5:03 AM EDT
Enrolling by invitation No phase listed Observational

Enabling Microbiomics- Driven Personalized Nutrition

NCT06657001
View directory record Official record
Conditions
Inflammatory Bowel Disease (IBD), Irritable Bowel Syndrome (IBS), Celiac Disease, Diarrhea, Constipation, Microbiome, Crohn's Disease, UC - Ulcerative Colitis, Microscopic Colitis, Functional Dyspepsia
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
4,001 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Jul 22, 2026, 5:03 AM EDT
Completed Phase 2 Interventional Results available

Randomized, Double-blind, Dose-range-finding, Phase 2 Study of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

NCT00460811
View directory record Official record
Conditions
Irritable Bowel Syndrome With Constipation
Interventions
Linaclotide Acetate, Matching placebo
Drug
Lead sponsor
Ironwood Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
79
States / cities
Huntsville, Alabama • Chandler, Arizona • Tuscon, Arizona + 76 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2013 · Synced Jul 22, 2026, 5:03 AM EDT
Terminated Phase 3 Interventional Results available

A Study of Prucalopride For Functional Constipation in Children and Teenagers

NCT04759833
View directory record Official record
Conditions
Constipation
Interventions
Prucalopride, Placebo
Drug · Other
Lead sponsor
Takeda
Industry
Eligibility
6 Months to 17 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
41
States / cities
Phoenix, Arizona • Tucson, Arizona • Anaheim, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2024 · Synced Jul 22, 2026, 5:03 AM EDT
Completed Not applicable Interventional

Biofeedback Treatment for Functional Constipation

NCT00502957
View directory record Official record
Conditions
Constipation
Interventions
Biofeedback
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2010 · Synced Jul 22, 2026, 5:03 AM EDT
Completed Phase 2 Interventional

Phase 2 Study of MD-1100 Acetate on Gastrointestinal Transit in Patients With C-IBS

NCT00258193
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
MD-1100 Acetate
Drug
Lead sponsor
Ironwood Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 19, 2006 · Synced Jul 22, 2026, 5:03 AM EDT
Completed No phase listed Observational

Efficacy of Psychological Therapies in Patients With Functional Bowel Disorders

NCT04060121
View directory record Official record
Conditions
IBS - Irritable Bowel Syndrome, Constipation
Interventions
Not listed
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 28, 2024 · Synced Jul 22, 2026, 5:03 AM EDT
Completed Phase 2 Interventional

A Proof of Concept Study of Pradigastat in Patients With Functional Constipation

NCT04620161
View directory record Official record
Conditions
Functional Constipation
Interventions
Pradigastat Tablets 20mg, Pradigastat Tablets 40mg, Pradigastat Tablets 20mg matching Placebo, Pradigastat Tablets 40mg matching Placebo
Drug
Lead sponsor
Anji Pharma
Industry
Eligibility
18 Years to 70 Years
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
5
States / cities
Meridian, Idaho • Evanston, Illinois • Las Vegas, Nevada + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2022 · Synced Jul 22, 2026, 5:03 AM EDT
Completed Phase 3 Interventional Results available

Long-term Safety of Linaclotide in Pediatric Participants With FC or IBS-C

NCT04166058
View directory record Official record
Conditions
Irritable Bowel Syndrome With Constipation, Functional Constipation
Interventions
Irritable Bowel Syndrome with Constipation (IBS-C) participants (LIN-MD-63 and LIN-MD-64 completers), Functional Constipation (FC) participants (LIN-MD-62 and LIN-MD-64 completers)
Drug
Lead sponsor
AbbVie
Industry
Eligibility
6 Years to 18 Years
Enrollment
381 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
65
States / cities
Birmingham, Alabama • Foley, Alabama • Saraland, Alabama + 50 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2026 · Synced Jul 22, 2026, 5:03 AM EDT
Terminated Phase 2 Interventional Results available

Olorinab in Irritable Bowel Syndrome With Predominant Constipation (IBS-C) and Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D)

NCT04043455
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Olorinab, Placebo
Drug
Lead sponsor
Arena Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
273 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
69
States / cities
Birmingham, Alabama • Huntsville, Alabama • Chandler, Arizona + 60 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2025 · Synced Jul 22, 2026, 5:03 AM EDT
Completed Phase 1Phase 2 Interventional

Effect of TU-100 on Rectal Compliance, Rectal Sensation and Small Bowel and Colonic Transit in Females With Constipation

NCT01139216
View directory record Official record
Conditions
Functional Constipation, Gastric Emptying, Whole Gut Transit, Small Bowel Transit, Colonic Transit, Rectal Compliance, Rectal Sensation
Interventions
Daikenchuto (TU-100), Placebo
Drug
Lead sponsor
Tsumura USA
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 13, 2013 · Synced Jul 22, 2026, 5:03 AM EDT
Completed Not applicable Interventional Results available

Effects of Lubiprostone on Gastrointestinal Transit & pH in Irritable Bowel Syndrome (IBS) With Constipation

NCT01162863
View directory record Official record
Conditions
Irritable Bowel Syndrome, Constipation
Interventions
Lubiprostone, Placebo, Smartpill wireless motility capsule
Drug · Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 26, 2017 · Synced Jul 22, 2026, 5:03 AM EDT
Completed Not applicable Interventional

Impact of Defecation Posture on Ease of First Bowel Movement Following Posterior Repair

NCT06253689
View directory record Official record
Conditions
Postoperative Constipation, Pelvic Organ Prolapse Vaginal Surgery, Defecation Function
Interventions
Defecation Posture Modification Device
Device
Lead sponsor
TriHealth Inc.
Other
Eligibility
18 Years and older · Female only
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
3
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 17, 2025 · Synced Jul 22, 2026, 5:03 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Study of NGM282 in Subjects With Functional Constipation and Healthy Individuals

NCT02649062
View directory record Official record
Conditions
Functional Constipation
Interventions
NGM282, Placebo
Biological · Other
Lead sponsor
NGM Biopharmaceuticals, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 29, 2018 · Synced Jul 22, 2026, 5:03 AM EDT
Completed Phase 3 Interventional

Treatment of Functional Bowel Disorders

NCT00006157
View directory record Official record
Conditions
Irritable Bowel Syndrome, Constipation, Abdominal Pain, Functional Colonic Diseases
Interventions
Desipramine, Cognitive Behavioral Treatment
Drug · Behavioral
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 65 Years · Female only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2001
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 12, 2010 · Synced Jul 22, 2026, 5:03 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Adherence/Outcomes After Use of Constipation Action Plan

NCT03821532
View directory record Official record
Conditions
Constipation - Functional
Interventions
Constipation Action Plan
Other
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
4 Years to 8 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Wilmington, Delaware
Source: ClinicalTrials.gov public record
Updated Jan 30, 2019 · Synced Jul 22, 2026, 5:03 AM EDT
Terminated Phase 3 Interventional

The Effect of Tegaserod on Patterns of Flow in the Small Bowel of Patients With Irritable Bowel Syndrome (IBS)

NCT00171431
View directory record Official record
Conditions
Constipation Predominant, Irritable Bowel Syndrome (IBS-C)
Interventions
Tegaserod
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 19, 2012 · Synced Jul 22, 2026, 5:03 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effect of Preoperative Fiber on Postoperative Bowel Function

NCT04882995
View directory record Official record
Conditions
Constipation, Prolapse, Vaginal
Interventions
Psyillium fiber
Dietary Supplement
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years and older · Female only
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 27, 2022 · Synced Jul 22, 2026, 5:03 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Efficacy and Safety of Vibegron Administered Orally for 12 Weeks to Women With Irritable Bowel Syndrome

NCT03806127
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Vibegron, Placebo
Drug
Lead sponsor
Urovant Sciences GmbH
Industry
Eligibility
18 Years to 70 Years · Female only
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
41
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 35 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2021 · Synced Jul 22, 2026, 5:03 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess Adverse Events and Change in Disease Activity in Pediatric Participants (Age 6 Months to <2 Years) With Functional Constipation Who Are Treated With Linaclotide

NCT05760313
View directory record Official record
Conditions
Functional Constipation
Interventions
Linaclotide, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
6 Months to 23 Months
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
18
States / cities
Phoenix, Arizona • Hot Springs, Arkansas • Anaheim, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2026 · Synced Jul 22, 2026, 5:03 AM EDT
Completed Phase 2 Interventional Results available

A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 6-17 Years Who Fulfill Modified Rome III Criteria for Child/Adolescent Functional Constipation (FC)

NCT02559570
View directory record Official record
Conditions
Functional Constipation in Children Ages 6-17 Years
Interventions
Placebo, LIN Dose A, LIN Dose B, LIN Dose C, LIN 145 µg
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
6 Years to 17 Years
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
60
States / cities
Hot Springs, Arkansas • Little Rock, Arkansas • Anaheim, California + 51 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2019 · Synced Jul 22, 2026, 5:03 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Adherence and Outcomes in Functional Constipation With a Constipation Action Plan

NCT04614935
View directory record Official record
Conditions
Adherence, Medication, Functional Constipation, Pediatric ALL, Survey, Family Life
Interventions
Action Plan
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
4 Years to 8 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 14, 2022 · Synced Jul 22, 2026, 5:03 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Effects of ROSE-010 on GI Transit in Constipation Predominant Irritable Bowel Syndrome (C-IBS) Patients

NCT01056107
View directory record Official record
Conditions
Irritable Bowel Syndrome Constipation Predominant
Interventions
ROSE-010, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 30, 2013 · Synced Jul 22, 2026, 5:03 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of Neostigmine and Glycopyrrolate

NCT04027972
View directory record Official record
Conditions
Spinal Cord Injuries, Constipation, Fecal Incontinence, Neurogenic Bowel
Interventions
Combination of Neostigmine and Glycopyrrolate, I-Box by Dynatronics
Drug · Device
Lead sponsor
James J. Peters Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 70 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Jul 22, 2026, 5:03 AM EDT